Metropolitan Life Insurance Co. NY Reduces Position in Owens & Minor (OMI)

Metropolitan Life Insurance Co. NY reduced its position in shares of Owens & Minor (NYSE:OMI) by 63.5% in the 4th quarter, Holdings Channel reports. The firm owned 35,274 shares of the company’s stock after selling 61,256 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Owens & Minor were worth $666,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Vident Investment Advisory LLC lifted its holdings in Owens & Minor by 19.5% during the 4th quarter. Vident Investment Advisory LLC now owns 103,564 shares of the company’s stock worth $1,956,000 after purchasing an additional 16,912 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in Owens & Minor by 341.5% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 10,626 shares of the company’s stock worth $200,000 after purchasing an additional 8,219 shares during the last quarter. Teachers Advisors LLC lifted its holdings in Owens & Minor by 4.0% during the 4th quarter. Teachers Advisors LLC now owns 113,226 shares of the company’s stock worth $2,138,000 after purchasing an additional 4,360 shares during the last quarter. Paloma Partners Management Co lifted its holdings in Owens & Minor by 540.4% during the 4th quarter. Paloma Partners Management Co now owns 83,932 shares of the company’s stock worth $1,585,000 after purchasing an additional 70,825 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Owens & Minor during the 4th quarter worth approximately $15,966,000. 96.90% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Owens & Minor stock opened at $15.84 on Monday. Owens & Minor has a one year low of $14.26 and a one year high of $34.97. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.91 and a current ratio of 1.67. The firm has a market cap of $974.41, a price-to-earnings ratio of 9.84, a P/E/G ratio of 0.96 and a beta of 1.06.

Owens & Minor (NYSE:OMI) last posted its quarterly earnings data on Wednesday, February 14th. The company reported $0.35 EPS for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.01. Owens & Minor had a return on equity of 9.63% and a net margin of 0.78%. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.34 billion. During the same quarter last year, the company earned $0.52 EPS. The company’s revenue was up .9% on a year-over-year basis. equities research analysts expect that Owens & Minor will post 2.06 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 30th. Stockholders of record on Thursday, March 15th were paid a $0.26 dividend. This is a positive change from Owens & Minor’s previous quarterly dividend of $0.26. The ex-dividend date of this dividend was Wednesday, March 14th. This represents a $1.04 annualized dividend and a dividend yield of 6.57%. Owens & Minor’s dividend payout ratio (DPR) is presently 64.60%.

OMI has been the subject of several research reports. Bank of America assumed coverage on Owens & Minor in a report on Tuesday, February 27th. They set a “buy” rating and a $19.00 price target for the company. Zacks Investment Research upgraded Owens & Minor from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. ValuEngine lowered Owens & Minor from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Barclays assumed coverage on Owens & Minor in a research note on Thursday, March 8th. They set an “underweight” rating and a $16.00 price objective on the stock. Finally, JPMorgan Chase lowered their price objective on Owens & Minor from $21.00 to $20.00 and set an “underweight” rating on the stock in a research note on Thursday, February 15th. Six investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $24.28.

ILLEGAL ACTIVITY NOTICE: “Metropolitan Life Insurance Co. NY Reduces Position in Owens & Minor (OMI)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3342922/metropolitan-life-insurance-co-ny-reduces-position-in-owens-minor-omi.html.

About Owens & Minor

Owens & Minor, Inc is a healthcare services company that connects the world of medical products to the point of care. The Company provides supply chain assistance to the providers of healthcare services and the manufacturers of healthcare products, supplies and devices. The Company’s segments include Domestic, International and Clinical & Procedural Solutions (CPS).

Want to see what other hedge funds are holding OMI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Owens & Minor (NYSE:OMI).

Institutional Ownership by Quarter for Owens & Minor (NYSE:OMI)

Receive News & Ratings for Owens & Minor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Owens & Minor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

FUNCoin  Price Tops $0.0177 on Exchanges
FUNCoin Price Tops $0.0177 on Exchanges
Comparing Haynes International  & Gerdau
Comparing Haynes International & Gerdau
Civeo  to Release Quarterly Earnings on Friday
Civeo to Release Quarterly Earnings on Friday
Beneficial Bancorp  Releases  Earnings Results, Hits Estimates
Beneficial Bancorp Releases Earnings Results, Hits Estimates
Contrasting Post  & General Mills
Contrasting Post & General Mills
Critical Analysis: Biocept  and Its Competitors
Critical Analysis: Biocept and Its Competitors


Leave a Reply

© 2006-2018 Ticker Report. Google+.